Ultra-thinly traded nano cap Plus Therapeutics (NASDAQ:PSTV) is up 114% premarket on robust volume after reporting Q2 results after the close yesterday that did not feature anything noteworthy to justify the action.
In H2, it plans to initiate a Phase 2 study (assuming the FDA signs off on the protocol) evaluating DocePLUS in small cell lung cancer patients who have progressed after first-line chemo.
On the working capital front, at the end of June it had $4.5M in cash and equivalents while operations consumed ($4.8M) in H1.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.